OMT-111

OMT-111 is a small molecule drug developed as a cancer cell metabolism modulator with potential antineoplastic activity. Its primary mechanism of action is the inhibition of pyruvate dehydrogenase kinase (PDH), which disrupts cancer cell metabolism and may suppress tumor growth. The drug is being investigated for use in patients with terminal stage solid tumors that are resistant to standard therapies, including metastatic colorectal cancer, breast cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and small cell lung cancer. Developed by MetiMedi Pharmaceuticals, OMT-111 has reached Phase II clinical trials in several indications[1][2][3][4][5][6][7].

Other names

cancer cell metabolism modulator OMT-111calcium lactate (OMT-111)